Human Brain Organoids: A New Model to Study Cryptococcus neoformans Neurotropism
Journal of Fungi · 19.07.2025 · 11 (7) · 539
DOI: 10.3390/jof11070539 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Fungi, online erschienen am 19.07.2025. Verfasst von Alfred T Harding und 3 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA 02139, USA. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NCI NIH HHS, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
With the rise in immunocompromised individuals and patients with immune-related comorbidities such as COVID-19, the rate of fungal infections is growing. This increase, along with the current plateau in antifungal drug development, has made understanding the pathogenesis and dissemination of these organisms more pertinent than ever. The mouse model of fungal infection, while informative on a basic scientific level, has severe limitations in terms of translation to the human disease. Here we present data supporting the implementation of the human cerebral organoid model, which is generated from human embryonic stem cells and accurately recapitulates relevant brain cell types and structures, to study fungal infection and dissemination to the central nervous system (CNS). This approach provides direct insight into the relevant pathogenesis of specific fungal organisms in human tissues where in vivo models are impossible. With this model system we assessed the specific brain tropisms and cellular effects of fungal pathogens known to cross the blood–brain barrier (BBB), such as Cryptococcus neoformans. We determined the effects of this fungal pathogen on the overall gross morphology, cellular architecture, and cytokine release from these model organoids. Furthermore, we demonstrated that C. neoformans penetrates and invades the organoid tissue and remains present throughout the course of infection. These results demonstrate the utility of this new model to the field and highlight the potential for this system to elucidate fungal pathogenesis to develop new therapeutic strategies to prevent and treat the disseminated stages of fungal diseases such as cryptococcal meningitis.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
- Department of Microbiology, Harvard Medical School, Boston, MA 02115, USA.
- Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.
- Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.
- Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
- Division of Infectious Disease, Department of Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA.
ORCID-Profile: Alfred T Harding, Lee Gehrke, Jatin M Vyas, Hannah Brown Harding
Förderung
- NIAID NIH HHS
- NCI NIH HHS
- National Institute of Allergy and Infectious Diseases
- NCI
- NIH
- BroadIgnite Fellowship
- Barbara K. Ostrom (1978) Bioinformatics and Computing Core Facility of the Swanson Biotechnology Center
Zitieren
APA
Harding, A. T., Gehrke, L., Vyas, J. M., & Harding, H. B. (2025). Human Brain Organoids: A New Model to Study Cryptococcus neoformans Neurotropism. Journal of Fungi, 11(7), 539. https://doi.org/10.3390/jof11070539
Vancouver
Harding AT, Gehrke L, Vyas JM, Harding HB. Human Brain Organoids: A New Model to Study Cryptococcus neoformans Neurotropism. Journal of Fungi. 2025;11(7):539. doi:10.3390/jof11070539
BibTeX
@article{Harding2025,
author = {Harding, Alfred T and Gehrke, Lee and Vyas, Jatin M and Harding, Hannah Brown},
title = {Human Brain Organoids: A New Model to Study Cryptococcus neoformans Neurotropism},
journal = {Journal of Fungi},
year = {2025},
volume = {11},
number = {7},
pages = {539},
doi = {10.3390/jof11070539}
}
EUVIMED